Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof

Patent metadata

Field	Value
Publication number	US-9084743-B2
Application number	US-80799110-A
Country	US
Kind code	B2
Filing date	Sep 16, 2010
Priority date	Sep 17, 2009
Publication date	Jul 21, 2015
Grant date	Jul 21, 2015

Abstract

Provided herein are stable co-formulations of immunoglobulin and hyaluronidase that are stable to storage in liquid form at room temperature for at least 6 months and at standard refrigerator temperatures for 1-2 years. Such co-formulations can be used in methods of treating IG-treatable diseases or conditions by subcutaneous administration.

First claim

The invention claimed is:

1. A stable composition formulated for subcutaneous administration, wherein:
the stable composition contains hyaluronidase and immune globulin (IG);
the stable composition is a liquid co-formulation;
the composition has a pH of between 4 or about 4 to 5 or about 5, inclusive; and
the composition comprises:
(a) immune globulin (IG) at a concentration that is at least 10% w/v;
a soluble hyaluronidase at a concentration that is at least 50 U/mL and is present in an amount sufficient to allow for the subcutaneous administration of the composition at a single injection site at an infusion rate equal to or greater than the intravenous infusion rate for intravenous immunoglobulin; and
an alkali metal chloride salt at a concentration of 0.05 M to 0.25 M, whereby the co-formulated composition is stable at temperatures of 28° C. to 32° C. for at least 6 months; or

(b) immune globulin (IG) at a concentration that is at least 10% w/v;
a soluble hyaluronidase at a concentration that is at least 50 U/mL and is present at a ratio of at least 100 Units (U) of hyaluronidase per gram (g) of the IG; and
an alkali metal chloride salt at a concentration of 0.05 M to 0.25 M, whereby the co-formulated composition is stable at temperatures of 28° C. to 32° C. for at least 6 months.

2. The stable composition of claim 1 , further comprising an amino acid stabilizer at a concentration that is at least 0.1 M.

3. The stable composition of claim 2 , wherein the amino acid stabilizer is selected from among alanine, histidine, arginine, lysine, ornithine, isoleucine, valine, methionine, glycine and proline.

4. The stable composition of claim 2 , wherein the amino acid stabilizer is at a concentration that is 0.25 M or at least 0.25 M.

5. The stable composition of claim 1 , wherein the concentration of IG is at least 20% w/v.

6. The stable composition of claim 1 , wherein the concentration of IG is between at or about 10% w/v to at or about 20% w/v.

7. The stable composition of claim 1 , wherein the IG is from human plasma.

8. The stable composition of claim 1 , wherein the IG is purified from human plasma by a purification method comprising alcohol fractionation.

9. The stable composition of claim 8 , wherein the IG is further purified by any one or more of a polyethylene glycol (PEG) precipitation, ion-exchange chromatography, enzymatic cleavage, diafiltration or ultrafiltration.

10. The stable composition of claim 1 , wherein the IG contains greater than 95% IgG.

11. The stable composition of claim 1 , wherein the alkali metal chloride salt is KCl or NaCl.

12. The stable composition of claim 1 , wherein the concentration of NaCl is at least 0.15 M.

13. The stable composition of claim 1 , wherein the soluble hyaluronidase is a PH20, or a truncated form thereof.

14. The stable composition of claim 13 , wherein the PH20 is selected from an ovine, bovine or truncated human PH20.

15. The stable composition of claim 14 , wherein PH20 is a truncated human PH20 and the truncated human PH20 is selected from among polypeptides having a sequence of amino acids set forth in any of SEQ ID NOS:4-9, or variants thereof having at least 91% sequence identity to any of SEQ ID NOS:4-9.

16. The stable composition of claim 1 , wherein the soluble hyaluronidase is a composition designated rHuPH20.

17. The stable composition of claim 1 , wherein the soluble hyaluronidase is at a concentration that is 50 U/mL to 500 U/mL.

18. The stable composition of claim 1 , wherein the soluble hyaluronidase is at a ratio of 100 U of hyaluronidase per gram of the IG to 3000 U of hyaluronidase per gram of the IG.

19. The stable composition of claim 1 that in concentrated form has a pH of 4.4 to 4.9, inclusive.

20. The stable composition of claim 1 , wherein the co-formulation is formulated for multiple dosage administration or for single dosage administration.

21. The stable composition of claim 1 that is formulated for single dosage administration in an amount sufficient to treat an IG-treatable disease or condition when administered daily, weekly, biweekly, every 2-3 weeks, every 3-4 weeks or monthly.

22. The stable composition of claim 1 , wherein the amount of IG in the co-formulation is substantially the same as the amount in a single dosage administration when administered intravenously for treatment of an IG-treatable disease or condition.

23. The stable composition of claim 1 , wherein the co-formulation is formulated for single dosage administration and the amount of IG is or is about at least 1 gram (g) to 200 g.

24. The stable composition of claim 1 , wherein the co-formulation is formulated for single dosage administration and the amount of hyaluronidase in the composition is or is about at least 500 Units, 1000 Units, 2000 Units, 5000 Units, 10,000 Units, 30,000 Units, 40,000 Units, 50,000 Units, 60,000 Units, 70,000 Units, 80,000 Units, 90,000 Units, 100,000 Units or more.

25. A container, comprising a stable composition of claim 1 .

26. A container of claim 25 that is a tube, bottle, vial or syringe and optionally includes a needle for injection.

27. A kit, comprising the container of claim 25 , and a means for infusing the composition.

28. The stable composition of claim 1 that comprises:
immune globulin (IG) at a concentration that is at least 10% w/v;
a soluble hyaluronidase at a concentration that is 50 U/mL to 500 U/mL and is present at a ratio of at least 100 Units (U) of hyaluronidase per gram (g) of the IG; and
an alkali metal chloride salt at a concentration of 0.05 M to 0.25 M, whereby the co-formulated composition is stable at temperatures of 28° C. to 32° C. for at least 6 months.

29. The stable composition of claim 1 that comprises:
immune globulin (IG) at a concentration that is at least 10% w/v;
a soluble hyaluronidase at a concentration that is 50 U/mL to 500 U/mL and is present in an amount sufficient to allow for the subcutaneous administration of the composition at a single injection site at an infusion rate equal to or greater than the intravenous infusion rate for intravenous immunoglobulin; and
an alkali metal chloride salt at a concentration of 0.05 M to 0.25 M, whereby the co-formulated composition is stable at temperatures of 28° C. to 32° C. for at least 6 months.

Assignees

• Teschner Wolfgang
• Svatos Sonja
• Bruckschwaiger Leopold
• Weber Alfred
• Schwarz Hans-Peter
• Lei Laura
• Baxter Int
• Baxter Healthcare Sa

Inventors

• Teschner Wolfgang
• Svatos Sonja
• Bruckschwaiger Leopold
• Weber Alfred
• Schwarz Hans-Peter
• Lei Laura

Classifications

• A61P37/02

  Immunomodulators · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P9/14

  Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title